Peptides Similar to Zovaglutide
Compare Zovaglutide with related peptides and alternatives
📌TL;DR
- •2 similar peptides identified
- •Semaglutide: High - Both are GLP-1 receptor agonists using fatty acid acylation for half-life extension. Semaglutide uses a single C18 fatty diacid (weekly dosing); zovaglutide uses dual fatty acid chains (monthly dosing).
- •Maritide: Moderate - Both are once-monthly injectable obesity therapies. However, maritide is an anti-GIPR antibody fused to GLP-1 agonist peptides, while zovaglutide is a pure GLP-1 RA with extended half-life.
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Zovaglutide (current) | - | - |
| Semaglutide | High - Both are GLP-1 receptor agonists using fatty acid acylation for half-life extension. Semaglutide uses a single C18 fatty diacid (weekly dosing); zovaglutide uses dual fatty acid chains (monthly dosing). | Dosing frequency is the key difference: semaglutide is weekly, zovaglutide is monthly. Semaglutide has extensive phase 3 data and FDA approval; zovaglutide has phase 2 data only. Semaglutide is also available in oral formulation. |
| Maritide | Moderate - Both are once-monthly injectable obesity therapies. However, maritide is an anti-GIPR antibody fused to GLP-1 agonist peptides, while zovaglutide is a pure GLP-1 RA with extended half-life. | Maritide has a dual mechanism (GLP-1 agonism + GIPR antagonism) via antibody-peptide fusion. Zovaglutide is a single-mechanism GLP-1 RA with dual fatty acid acylation. Different molecular architectures and potentially different efficacy/safety profiles. |
SemaglutideHigh - Both are GLP-1 receptor agonists using fatty acid acylation for half-life extension. Semaglutide uses a single C18 fatty diacid (weekly dosing); zovaglutide uses dual fatty acid chains (monthly dosing).
Differences
Dosing frequency is the key difference: semaglutide is weekly, zovaglutide is monthly. Semaglutide has extensive phase 3 data and FDA approval; zovaglutide has phase 2 data only. Semaglutide is also available in oral formulation.
Advantages
Once-monthly dosing reduces injection burden from 52 to 12 per year. Lower GI-related discontinuation rate (1.3% vs 4-7% with semaglutide).
Disadvantages
Investigational with no regulatory approval. Limited to 24-week data (vs 68+ weeks for semaglutide). No oral formulation. Tested primarily in Chinese population.
MaritideModerate - Both are once-monthly injectable obesity therapies. However, maritide is an anti-GIPR antibody fused to GLP-1 agonist peptides, while zovaglutide is a pure GLP-1 RA with extended half-life.
Differences
Maritide has a dual mechanism (GLP-1 agonism + GIPR antagonism) via antibody-peptide fusion. Zovaglutide is a single-mechanism GLP-1 RA with dual fatty acid acylation. Different molecular architectures and potentially different efficacy/safety profiles.
Advantages
Simpler mechanism may mean a more predictable safety profile. Dual fatty acid approach may be more cost-effective to manufacture than antibody fusions.
Disadvantages
Single-mechanism (GLP-1 only) may limit maximal efficacy compared to dual-mechanism agents targeting additional pathways.
Peptides Related to Zovaglutide#
Zovaglutide is positioned in the rapidly evolving GLP-1 RA landscape, where its key differentiator is once-monthly dosing through the dual-fatty acid chain design. The most relevant comparisons are with other GLP-1 RAs at various dosing frequencies and with other long-acting obesity therapies.
Semaglutide (Wegovy/Ozempic)#
Semaglutide is the current market-leading GLP-1 RA for obesity and the most direct comparator to zovaglutide, as both use fatty acid acylation for half-life extension.
Mechanism comparison: Both activate the GLP-1 receptor. Semaglutide uses a single C18 fatty diacid chain for albumin binding (half-life ~7 days, weekly dosing). Zovaglutide uses dual fatty acid chains for enhanced albumin binding (half-life 2-4x longer, monthly dosing).
Efficacy comparison (cross-trial, indirect):
- Zovaglutide 160 mg Q4W: -13.8% at 24 weeks (phase 2)
- Semaglutide 2.4 mg weekly: ~-12% at 24 weeks, -15.3% at 68 weeks (STEP 1, phase 3)
Key trade-off: Zovaglutide offers monthly dosing convenience but lacks the extensive evidence base, regulatory approval, and oral formulation option of semaglutide.
Tirzepatide (Zepbound/Mounjaro)#
Tirzepatide is a dual GIP/GLP-1 receptor agonist with the highest weight loss among approved agents.
Mechanism comparison: Tirzepatide activates both GIP and GLP-1 receptors (dual incretin agonism). Zovaglutide activates GLP-1 receptors only. Tirzepatide's dual mechanism may contribute to its superior weight loss (~22% at 72 weeks).
Key trade-off: Tirzepatide achieves greater maximal weight loss but requires weekly dosing. Zovaglutide's monthly dosing is more convenient but may not match tirzepatide's peak efficacy.
Maritide (AMG 133, Amgen)#
Maritide is the most relevant comparison for once-monthly obesity therapies, as both target the same dosing frequency.
Mechanism comparison: Maritide is a bispecific molecule combining anti-GIPR antibody with GLP-1 agonist peptides (GIPR antagonism + GLP-1 agonism). Zovaglutide is a pure GLP-1 RA with extended pharmacokinetics. These represent fundamentally different approaches to achieving monthly dosing.
Key trade-off: Maritide's dual mechanism (different from tirzepatide's dual agonism) may offer unique metabolic benefits, while zovaglutide's simpler single-mechanism approach may have a more predictable safety profile and be easier to manufacture.
Summary Comparison#
| Feature | Zovaglutide | Semaglutide | Tirzepatide | Maritide |
|---|---|---|---|---|
| Mechanism | GLP-1 RA | GLP-1 RA | GIP + GLP-1 RA | Anti-GIPR + GLP-1 RA |
| Dosing | Monthly SC | Weekly SC/daily oral | Weekly SC | Monthly SC |
| Max WL (trials) | -13.8% (24 wk) | -15.3% (68 wk) | -22.5% (72 wk) | ~-14.5% (12 wk) |
| Phase | Phase 3 | Approved | Approved | Phase 2 |
| GI discontinuation | 1.3% | 4-7% | 4-6% | TBD |
| Developer | QL Biopharm | Novo Nordisk | Eli Lilly | Amgen |
Comparison Context#
Zovaglutide belongs to the Metabolic category of research peptides. Comparing Zovaglutide with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.
Detailed Comparisons#
The following peptides and compounds are most closely related to Zovaglutide in mechanism, indication, or therapeutic category:
Zovaglutide vs Semaglutide#
Similarity: High - Both are GLP-1 receptor agonists using fatty acid acylation for half-life extension. Semaglutide uses a single C18 fatty diacid (weekly dosing); zovaglutide uses dual fatty acid chains (monthly dosing).
Key Differences: Dosing frequency is the key difference: semaglutide is weekly, zovaglutide is monthly. Semaglutide has extensive phase 3 data and FDA approval; zovaglutide has phase 2 data only. Semaglutide is also available in oral formulation.
Advantages of Semaglutide: Once-monthly dosing reduces injection burden from 52 to 12 per year. Lower GI-related discontinuation rate (1.3% vs 4-7% with semaglutide).
Disadvantages of Semaglutide: Investigational with no regulatory approval. Limited to 24-week data (vs 68+ weeks for semaglutide). No oral formulation. Tested primarily in Chinese population.
Researchers choosing between Zovaglutide and Semaglutide should consider the development stage, available evidence, and specific research objectives when making their selection.
Zovaglutide vs Maritide#
Similarity: Moderate - Both are once-monthly injectable obesity therapies. However, maritide is an anti-GIPR antibody fused to GLP-1 agonist peptides, while zovaglutide is a pure GLP-1 RA with extended half-life.
Key Differences: Maritide has a dual mechanism (GLP-1 agonism + GIPR antagonism) via antibody-peptide fusion. Zovaglutide is a single-mechanism GLP-1 RA with dual fatty acid acylation. Different molecular architectures and potentially different efficacy/safety profiles.
Advantages of Maritide: Simpler mechanism may mean a more predictable safety profile. Dual fatty acid approach may be more cost-effective to manufacture than antibody fusions.
Disadvantages of Maritide: Single-mechanism (GLP-1 only) may limit maximal efficacy compared to dual-mechanism agents targeting additional pathways.
Researchers choosing between Zovaglutide and Maritide should consider the development stage, available evidence, and specific research objectives when making their selection.
Related Reading#
Frequently Asked Questions About Zovaglutide
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer